Company intelligence / Profile preview
Invectys
Houston, Texas, USAinvectys.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
INVAC-1 completed Phase I clinical trial showing safety and well-tolerated results, with 60% of patients with late stage IV cancers showing stabilization. IVS-3001 received FDA Fast Track designation for treatment of Renal Cell Carcinoma. The company has initiated a Phase 1/2a clinical trial for solid tumors[1][5].
- Therapeutic areas
- Oncology
- Modalities
- Therapeutic vaccinesCAR-T cell therapyImmunotherapy
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
MD Anderson Cancer Center
Beyond the preview
Go deeper on Invectys.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Invectys.